Siddhartha G. Kapnadak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Siddhartha G. Kapnadak has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
- Kathleen J. Ramos
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington
12 shared publications Christopher H. Goss
Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, USA
7 shared publications- Christopher Hooper Goss
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA, USA; CF Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA, USA; Division of Pulmonary and Sleep Medicine, Department of Pediatrics, University of Washington, Seattle, WA, USA
7 shared publications - Erika D. Lease
University of Washington
5 shared publications Kathleen J. Ramos
Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, USA
5 shared publications- Nora Burdis
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle WA, United States
4 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by Springer Nature in BMC Pulmonary Medicine
Assessing the need for reproductive genetic counseling among adults with cystic fibrosis
- 21 August 2026
- Published by Springer Nature in BMC Pulmonary Medicine
Open AccessAssessing the need for reproductive genetic counseling among adults with cystic fibrosis
- 8 June 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (9) , 1470-1473
Approach to prevention and management of chronic lung allograft dysfunction in North American lung transplant centers
- 8 June 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (9) , 1470-1473
Approach to prevention and management of chronic lung allograft dysfunction in North American lung transplant centers
- 2 July 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (5) , 929-934
Elexacaftor/tezacaftor/ivacaftor prescription in lung transplant recipients with cystic fibrosis in the US
- 2 July 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (5) , 929-934
Elexacaftor/tezacaftor/ivacaftor prescription in lung transplant recipients with cystic fibrosis in the US
- Open Access
Airway complications after lung transplantation: Perioperative risk factors and clinical outcomes
- 5 May 2025
- Published by Elsevier in Patient Education and Counseling
- Vol. 137, 108822
Personal narratives to support learning about lung transplant for people with cystic fibrosis
- 5 May 2025
- Published by Elsevier in Patient Education and Counseling
- Vol. 137, 108822
Personal narratives to support learning about lung transplant for people with cystic fibrosis
- 3 December 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (4) , 681-685
The prognostic value of single and repeated ≥10% FEV1 declines for chronic lung allograft dysfunction
- 3 December 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (4) , 681-685
The prognostic value of single and repeated ≥10% FEV1 declines for chronic lung allograft dysfunction
- Open Access
- 22 June 2024
- Published by Elsevier in CHEST Pulmonary
- Vol. 2 (4)
A Dramatic Decline in Lung Transplantation for Cystic Fibrosis in the United States
- 22 June 2024
- Published by Elsevier in CHEST Pulmonary
- Vol. 2 (4)
Open AccessA Dramatic Decline in Lung Transplantation for Cystic Fibrosis in the United States
- 25 November 2023
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (1) , 161-164
A longitudinal analysis of respiratory symptoms in people with cystic fibrosis with advanced lung disease on and off ETI
- 25 November 2023
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (1) , 161-164
A longitudinal analysis of respiratory symptoms in people with cystic fibrosis with advanced lung disease on and off ETI
- 7 October 2023
- Published by Taylor & Francis
- p. 444-464
Transplantation
Lung transplantation is an important treatment option for individuals with advanced cystic fibrosis (CF) lung disease. CF outcomes have improved dramatically, particularly since the advent of cystic fibrosis transmembrane conductance regulator (CFTR) modulators. Despite these advances, transplant will likely remain an important consideration for many patients who have disease progression in the coming decades due to intolerance of or lack of access to these novel treatments. Others with CF may require transplantation of extrapulmonary solid organs, most commonly the liver and pancreas. People with CF consistently look to their CF teams for guidance, and there is a need for providers to thus be familiar with lung and other organ transplantation. CF care teams must appropriately counsel their patients on transplant, refer for transplant in a timely manner, and participate in shared care after transplantation to improve the chance of successful outcomes. This chapter reviews important considerations for people with CF before and after lung and other solid organ transplantation.
- 7 October 2023
- Published by Taylor & Francis
- p. 444-464
Transplantation
Lung transplantation is an important treatment option for individuals with advanced cystic fibrosis (CF) lung disease. CF outcomes have improved dramatically, particularly since the advent of cystic fibrosis transmembrane conductance regulator (CFTR) modulators. Despite these advances, transplant will likely remain an important consideration for many patients who have disease progression in the coming decades due to intolerance of or lack of access to these novel treatments. Others with CF may require transplantation of extrapulmonary solid organs, most commonly the liver and pancreas. People with CF consistently look to their CF teams for guidance, and there is a need for providers to thus be familiar with lung and other organ transplantation. CF care teams must appropriately counsel their patients on transplant, refer for transplant in a timely manner, and participate in shared care after transplantation to improve the chance of successful outcomes. This chapter reviews important considerations for people with CF before and after lung and other solid organ transplantation.
- 3 October 2023
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (3) , 545-548
Patient perspectives on elexacaftor/tezacaftor/ivacaftor after lung transplant
- 3 October 2023
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (3) , 545-548
Patient perspectives on elexacaftor/tezacaftor/ivacaftor after lung transplant